WO2009124293A1 - Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets - Google Patents
Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets Download PDFInfo
- Publication number
- WO2009124293A1 WO2009124293A1 PCT/US2009/039552 US2009039552W WO2009124293A1 WO 2009124293 A1 WO2009124293 A1 WO 2009124293A1 US 2009039552 W US2009039552 W US 2009039552W WO 2009124293 A1 WO2009124293 A1 WO 2009124293A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amplification
- primers
- target
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Definitions
- the invention relates generally to methods for amplifying nucleic acids.
- the invention relates to methods for using the polymerase chain reaction to amplify multiple nucleic acid sequences.
- PCR polymerase chain reaction
- MDD molecular differential diagnostic
- Diagnostic testing of clinical samples to find one or more causative disease agents has, in the past, required that microorganisms be isolated and cultured. This may take days, however, and in many cases a diagnosis must be acted upon within hours if the patient's life is to be saved.
- Analysis of a single clinical sample to identify multiple organisms in order to determine which one(s) may be the causative agent(s) of disease is the desired method for MDD, and methods have been developed to better achieve that goal.
- multiplex PCR methods have been developed to amplify multiple nucleic acids within a sample in order to produce enough DNA/RNA to enable detection and identification of multiple organisms. Multiplex PCR has disadvantages, however.
- each target in a multiplex PCR reaction requires its own optimal reaction conditions, so increasing the number of targets requires that the reaction conditions for each individual target are less than optimal.
- multiple sets of high-concentration primers in a system often generate primer dimmers or give non-specific, background amplification. This lack of specificity also requires the additional steps of post-PCR clean-up and multiple post-hybridization washes. Crowded primers reduce the amplification efficiency by requiring the available enzymes and consuming substrates. Differences in amplification efficiency may lead to significant discrepancies in amplicon yields. For example, some toci may amplify very efficiently, while others amplify very inefficiently or fail to amplify at all. This potential for uneven amplification also makes it difficult to impossible to accurately perform end- point quantitative analysis.
- One method utilizes nested gene-specific primers used at very low concentrations to enrich the targets during the initial PCR cycling. Later, common primers are used to amplify all the targets. The entire reaction is performed in one tube, no additional rounds of PCR are required, and it does not require specialized instruments but may instead be performed using regular thermal cyclers. There are disadvantages to this method, however.
- the present invention relates to a method for amplifying nucleic acids to enable detection of those nucleic acids, the method comprising the steps of amplifying one or more target nucleic acids using high concentration, target-specific primers in a first amplification reaction, thereby producing at least one nucleic acid amplicon containing at least one common primer binding site, rescuing the at least one nucleic acid amplicon, and amplifying the at least one nucleic acid amplicon in a second amplification reaction utilizing common primers which bind to the at least one common primer binding site
- One aspect of the invention utilizes nested target- specific primers
- Target nucleic acids may comprise DNA and/or RNA, and may comprise DNA and/or RNA of viral, bacterial, and/or fungal origin, as well as genomic DNA and/or RNA of human or other animal origin
- Amplification may be performed by polymerase chain reaction (PCR) and/or RT-PCR
- the source of the target nucleic acids may be from one or more clinical,
- FIG. 1 is an illustration of the method of the invention, where F o represents forward-out primers; F i represents forward-in primers with a forward common primer tag (binding sequence); C f represents a forward common primer; R 1 represents a reverse-in primer with reverse common primer tag (binding sequence); R 0 represents a reverse-out primer; C r represents a reverse common primer; F a represents an additional forward primer; and R 3 represents an additional reverse primer, with these primers being positioned generally as indicated.
- F o represents forward-out primers
- F i represents forward-in primers with a forward common primer tag (binding sequence)
- C f represents a forward common primer
- R 1 represents a reverse-in primer with reverse common primer tag (binding sequence)
- R 0 represents a reverse-out primer
- C r represents a reverse common primer
- F a represents an additional forward primer
- R 3 represents an additional reverse primer, with these primers being positioned generally as indicated.
- the inventor has developed a new method for amplifying nucleic acids that may be used to detect the presence, and relative amounts present, of nucleic acids from viruses, bacteria, fungi, plant and/or animal cells for the evaluation of medical, environmental, food, and other samples to identify microorganisms and other agents within those samples.
- the method will be referred to herein as amplicon rescue multiplex polymerase chain reaction ("arm- PCR").
- arm- PCR PCR amplifications of target nucleic acids are performed sequentially in two different reaction systems.
- These systems may comprise separate columns, reaction containers, or sections of a chip, for example, containing the target nucleic acid(s), primers, enzymes, nucleotides (e.g., dNTPs) and buffers necessary to amplify the target nucleic acid(s) to produce amplicons.
- primers primers
- enzymes nucleotides
- buffers necessary to amplify the target nucleic acid(s) to produce amplicons.
- reaction system it is intended to describe an Eppendorf tube, reaction chamber, or other containment device into which the necessary primers, enzymes, nucleotides, buffers, and/or other reagents are placed in order to perform one or more cycles of at least one polymerase chain reaction.
- reaction system may therefore refer to the same reaction containment vessel, but a different component of reagents — particularly primers — for performing the desired amplification step.
- reaction containment vessel is intended to mean a tube, plate well, or other vessel having a sufficient internal volume to contain primers, enzymes, nucleotides, buffers, and/or other reagents necessary to provide a reaction system.
- the term “rescue” is intended to mean the separation of amplicons from at least a portion of the primers of the first amplification.
- PCR is intended to mean the polymerase chain reaction, and may include PCR and/or RT-PCR procedures. [011] In the first step of the method, high-concentration, target-specific, nested primers are used to perform a target-specific first amplification procedure.
- Primers are chosen from known sequences of viruses, bacteria, fungi, and/or other targets for which identification using nucleic acid detection is desired, and are specific for those target nucleic acids and/or closely related target nucleic acids.
- Target-specific primers may be used to amplify one or more (and preferably multiple) target nucleic acids of bacterial, viral, fungal, and/or other origin, for example.
- Nested primer concentration may generally be between 5-50 pmol. As illustrated in Fig.
- selected primers are "tagged" with additional nucleotides to provide an additional sequence that is not specific for the target nucleic acid(s) so that amplification of the target nucleic acid with such a primer will also incorporate into the resulting amplicon a binding site for a common primer that, unlike a target- specific primer, may be used to further amplify unrelated target nucleic acid amplicons (see A and B in Fig. 1).
- Amplification is performed for approximately 10- 15 cycles, the reaction is terminated, and the resulting amplicons are rescued from the reaction mix for use in a second, target-independent amplification procedure, comprising a polymerase chain reaction primed by common primers which will, in a relatively indiscriminate manner, provide amplification of unrelated nucleotide sequences represented by the variety of amplicons rescued from the target-specific reaction.
- Amplicon rescue is then performed to minimize or eliminate the primers of the first reaction, while providing amplicons for use in the second amplification using common primers.
- Amplicon rescue may be performed in a variety of ways. For example, a small sampling from the completed first amplification reaction may be taken to provide amplicons for the second amplification. When a small sample is taken, it provides sufficient numbers of amplicons for the second amplification, while significantly decreasing (e.g., diluting) the remaining numbers of primers of the first amplification.
- Amplicon rescue may also be performed by removing a significant portion of the contents of the reaction system of the first amplification and adding to the remaining contents the common primer(s) with the necessary enzyme(s), nucleotides, buffer(s), and/or other reagents to perform a second amplification utilizing the common primer(s) to amplify the rescued amplicons in a second reaction system.
- Separation techniques may also be utilized to rescue amplicons. Such techniques may rely on size differences between the primers and amplicons, on tags that have been attached to the amplicons, the primers, or both, or other methods known to those of skill in the art.
- the second amplification is performed in a different reaction system, which may or may not utilize the same reaction containment vessel.
- the second amplification amplifies the rescued amplicons using fresh buffer, nucleotides, and common primer(s). Common primers are chosen to provide efficient amplification of the rescued amplicons to provide significant numbers of copies of those amplicons at the end of the second amplification.
- the inventor By separating the reactions into a first, target-specific primer-driven amplification and a second, target-independent common primer-driven amplification, the inventor has developed a method that will provide specificity through the use of target-specific primers to amplify only the kinds and numbers of nucleic acids present from a particular target, and sensitivity achieved by the use of nested primers, the high concentration of target-specific primers, and the use of the common primer(s) to provide non-specific (target-independent) amplification at higher copy numbers.
- first amplification, amplicon rescue, and second amplification lends itself to automation Not only can these steps be performed within a relatively closed reaction system, which limits the possibility of contamination, but the combination of first amplification, amplicon rescue, and second amplification provided by the method produces a specific, sensitive detection method for multiple targets from multiple samples within a period of less than 2 hours [015]
- Target nucleic acids may be isolated from their respective sources by various means known to those of skill in the art Detection of amplicons produced by the method may also be performed by various means known to those of skill in the art, such as application of the amplicons from the second amplification step to
- the invention also provides primer kits for PCR amplification of target nucleotides, such kits comprising primers chosen from among the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11 SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37,
- a method for automation of the method may be provided where the amplifications, separation, and detection are performed using a "lab-on-chip" device in a closed system.
- a first, target-specific amplification may be performed in a first reaction system (PCRl), where nested, unlabeled, high-concentration target-specific primers may be pre-loaded, together with dNTPs, buffer and enzymes to perform the desired PCR or RT-PCR amplification.
- PCRl first reaction system
- nested, unlabeled, high-concentration target-specific primers may be pre-loaded, together with dNTPs, buffer and enzymes to perform the desired PCR or RT-PCR amplification.
- unused primers may be separated from nucleotide amplicons using capillary electrophoresis by means of electrodes activated between the PCRl (negative) and a waste chamber (positive) to separate the primers from the ampllcons.
- the electrode In the waste chamber may be turned off and a second reaction system (PCR2) positively charged.
- PCR2 second reaction system
- the larger molecular weight ampllcons may therefore migrate to the PCR2 chamber, where they are mixed with pre-loaded common primers and fresh enzymes, dNTPs and buffer.
- the PCR products may be electrophoretlcally moved to the detection charm berto be hybridized to probes covalently fixed onto beads, the position of the beads in an array representing specific molecular targets.
- Target detection may therefore be performed by imaging analysis, for example, where positive results may be indicated by bright beads, as ampllcons products may be labeled with fluorescent dyes or other chemical/biochemical labels. Unused PCR products and primers may then be removed and deposited in the waste chamber.
- a PCR chip may comprise a first reaction system fluldly connected to both a waste reservoir and a second reaction system, the waste reservoir and second reaction system each additionally comprising at least one electrode, the electrodes comprising a means for separating amplicons produced from the first reaction system.
- the second reaction system may be fluidly connected to a hybridization and detection chamber, the hybridization and detection chamber comprising microspheres, or beads, arranged so that the physical position of the beads is an indication of a specific target polynucleotide's presence in the sampled analyzed by means of the chip.
- the chip may be pre-loaded with reagents, or the reagents may be added by the user.
- pre-loaded reagents may include nested, high-concentration target- specific primers, dNTPs, polymerase enzymes, and buffer(s) for a first reaction system.
- the second reaction system may be preloaded with common primers, dNTPs, buffer, and polymerase enzymes.
- a patient sample may be loaded into at least one first reaction system by injecting the sample through soft, rubber-like polydimethylsiloxane (PDMS) material covering all or a portion of the chip.
- PDMS polydimethylsiloxane
- the first series of PCR cycles may be performed for the first amplification, to amplify the target sequences and to incorporate common primer binding sequences into at least a portion of the resulting amplicons.
- Amplicon products from the first reaction system may then be separated by on-chtp electrophoresis performed in the microfluidic channel, the first reaction system being fluidly connected to at least one second reaction system and at least one waste reservoir, each of the second reaction systems and waste reservoirs additionally comprising at least one electrode, the electrodes promoting movement of the amplicons and unused primers from the first amplification reaction to a second reaction system and a waste reservoir, respectively.
- Amplicons moved to a second PCR reaction system may then be then subjected to a second amplification using common primers to amplify amplicons into which at least one common primer binding site has been incorporated during the first amplification in the first reaction system.
- the PCR products may be moved by microfluidic electrophoresis from the second reaction system to at least one hybridization and detection chamber, a second reaction system being fluidly connected to at least one hybridization and detection chamber.
- a hybridization and detection chamber may be microspheres, or beads, forming an array, the physical position of the beads indicating the specific target for detection.
- a bead array may comprise from about 1 to about 200 targets, with each target being represented by from about 1 to about 100 beads. If a specific target is not represented by the appropriate primers in the first amplification reaction, a software mask may be used to cover the related beads so that they will not interfere with the analysis.
- the hybridization and detection chamber may be fluidly connected to at least one wash chamber and at least one detection chamber, the wash chamber comprising reagents to assist in the removal of unused, labeled, primers and probes to reduce background, and the detection chamber comprising reagents such as streptavidine-Quantum dots, or streptavidine-PE for labeling amplified DNA for imaging analysis.
- the wash chamber comprising reagents to assist in the removal of unused, labeled, primers and probes to reduce background
- the detection chamber comprising reagents such as streptavidine-Quantum dots, or streptavidine-PE for labeling amplified DNA for imaging analysis.
- the method of the invention may also be performed using a standard or modified PCR thermocycler.
- nucleotides, buffers, and primers may be loaded into standard PCR tubes in a first thermocycler for the first amplification.
- the contents of the tube may be removed by manual or automated means for rescue of the amplicons, and the newly-isolated amplicons may be placed into a second amplification tube where buffers, nucleotides, and enzyme(s) are introduced in order to perform the second amplification in the first or a second thermocycler, the thermocycler being programmed to cycle the reaction through the appropriate temperatures for the desired lengths of time.
- cycling times and the number of cycles may vary and may be determined by those of skill in the art.
- nested primers appear to improve the binding affinity of the polymerase, producing significantly more amplicons during the first amplification reaction.
- These amplicons may be produced from a variety of target polynucleotides within the sample, using a high concentration of target-specific primers.
- By incorporating into at least a portion of the amplicons during the first amplification at least one binding site for at least one common primer it is then possible, during the second amplification, to even more significantly increase the number of amplicons produced as a result of the amplification process.
- Common primers are chosen for their binding affinity and capacity to prime amplification during the second amplification.
- this three-step method (1 st amplification step, amplicon rescue, 2 nd amplification step), it is therefore possible to increase both the specificity and the sensitivity of the PCR process for identifying one or more target organism(s) from a sample containing multiple organisms.
- the inventor has discovered that this method does significantly increase both specificity and sensitivity, when compared to previously-described PCR methods.
- Automating the amplification-separation-amplification process enables the identification of a significant number of targets within a period of 1-3 hours, and has been shown to be effective for amplifying target nucleic acids from multiple microorganisms within a period of 1.5 hours, allowing rapid identification of a possible causative agent of disease to allow immediate steps to be taken toward treatment, isolation, implementation of public health plans for limiting exposure to epidemic-causing disease agents, bioterror agents, etc.
- Samples may be prepared for the PCR reactions by various means known to those of skill in the art. These methods may be provided as instructions provided with PCR kits containing buffers and enzymes, for example, or instructions may be obtained from various journal or patent publications. Methods for handling samples prior to preparation for the PCR amplification steps are also known to those of skill in the art, and may vary depending upon the source of the sample.
- Enzymes used for the amplifications are commercially available and may include, for example, Qiagen Multiplex mix or Qiagen Hot Start mix. Buffers are also commercially available, as are nucleotides (dNTPs) and other reagents.
- Thermocyclers are manufactured by and distributed by a variety of companies including, for example, Applied Biosystems and Bio-Rad. PCR reagent kits may also be obtained from various sources, including, for example, Qiagen (Gaithersburg, Maryland).
- the invention provides a method that is suitable for identifying a single microorganism or multiple microorganisms, for example, from a sample that may contain a variety of microorganisms.
- a sample may be obtained from a clinical specimen (e.g., blood, saliva, tissue), from an environmental sample (e.g., water, soil), from a food sample, or other source.
- a clinical specimen e.g., blood, saliva, tissue
- an environmental sample e.g., water, soil
- Microorganisms that may be identified may include various genera and species of bacteria, viruses, and other DNA and/or RNA- containing organisms.
- a method such as the Luminex xMAP ® technology may be utilized, and the detection step may be incorporated into the automated system along with the amplifications so that the automated system accomplishes the first amplification, the amplicon rescue, the second amplification, and detection.
- microspheres in suspension provide solid support for probe binding, also known as a "liquid chip” or “suspension array "
- probe binding also known as a "liquid chip” or "suspension array”
- xMAP ® technology molecular reactions take place on the surface of color-coded microspheres
- target-specific capture probes may be covalently linked to a specific set of color-coded microspheres
- Labeled PCR products are captured by the bead-bound capture probes in a hybridization suspension
- a microfluidics system delivers the suspension hybridization reaction mixture to a dual-laser detection device
- a red laser identifies each bead by its color-coding, while a green laser detects the hybridization signal associated with each bead
- Software is used to collect the data and report the results in a matter of seconds The data is reported in the form of mean fluorescence intensity (MFI)
- Example 1 An arm-PCR reaction was designed to amplify and detect pathogens responsible for food-borne diseases
- the target gene used for each pathogen is listed in Table 1 below Table 1
- Primers generated for each target are listed in Table 2.
- SupF and SupR indicate common primer sequences. Common primer sequences forming the tag for target-specific primers are shown in bold letters.
- F 0 , F 1 , R 1 and R 0 indicate the nested primers for each amplification target, while the D oligo indicates the detection probe that hybridizes to a specific sequence within the amplicon.
- the probe is covalently linked to a color coded bead for detection with the Luminex xMAP ® instrument.
- rfbE2 Fo AGGATTAGCTGTACATAGGC 13 rfbE2 Fi TTCTTAGCGTATTGGAGTCCGGCATGACGTTATAGGCTAC 14 rfbE2 Ri AATGTACAGTATTGCGTTTTGTGTTCTAACTGGGCTAATCC 15 rfbE2 Ro CGTG AT AT AAAATC ATC AG C 16 rfbE2 D /5AmMC12/GACAAATATCTGCGCTGCTAT 17
- a Qiagen Multiplex PCR kit was used to prepare a sample containing 44 ⁇ l of Multiplex Mix, 5 ⁇ l of primer mix, and 1 ⁇ l of template. Cycling conditions were as follows:
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09727817.0T ES2586457T3 (en) | 2008-04-03 | 2009-04-03 | Multiple polymerase chain reaction of amplicon rescue for multiple target amplification |
AU2009231582A AU2009231582B2 (en) | 2008-04-03 | 2009-04-03 | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
CN2009801189681A CN102066573A (en) | 2008-04-03 | 2009-04-03 | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
LTEP09727817.0T LT2271767T (en) | 2008-04-03 | 2009-04-03 | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
DK09727817.0T DK2271767T3 (en) | 2008-04-03 | 2009-04-03 | Amplikonredning-multiplex polymerase chain reaction for the amplification of multiple target |
JP2011503231A JP5811483B2 (en) | 2008-04-03 | 2009-04-03 | Amplicon Rescue Multiplex Polymerase Chain Reaction for Amplification of Multiple Targets |
SI200931497A SI2271767T1 (en) | 2008-04-03 | 2009-04-03 | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
EP09727817.0A EP2271767B1 (en) | 2008-04-03 | 2009-04-03 | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
BRPI0911082-8A BRPI0911082A2 (en) | 2008-04-03 | 2009-04-03 | Amplicon Rescue Multiplex Polymerase Chain Reaction for Multiple Target Amplifications |
HRP20160923TT HRP20160923T1 (en) | 2008-04-03 | 2016-07-21 | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
CY20161100781T CY1117891T1 (en) | 2008-04-03 | 2016-08-09 | MULTIPLE CHAIN RESPONSE MULTIPLAYER RESPONSE OF AMPLICONS TO MULTIPLE TARGETS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4225908P | 2008-04-03 | 2008-04-03 | |
US61/042,259 | 2008-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009124293A1 true WO2009124293A1 (en) | 2009-10-08 |
Family
ID=41133627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/039552 WO2009124293A1 (en) | 2008-04-03 | 2009-04-03 | Amplicon rescue multiplex polymerase chain reaction for amplificaton of multiple targets |
Country Status (17)
Country | Link |
---|---|
US (3) | US7999092B2 (en) |
EP (1) | EP2271767B1 (en) |
JP (2) | JP5811483B2 (en) |
CN (3) | CN102066573A (en) |
AU (1) | AU2009231582B2 (en) |
BR (1) | BRPI0911082A2 (en) |
CY (1) | CY1117891T1 (en) |
DK (1) | DK2271767T3 (en) |
ES (1) | ES2586457T3 (en) |
HK (1) | HK1245846A1 (en) |
HR (1) | HRP20160923T1 (en) |
HU (1) | HUE029914T2 (en) |
LT (1) | LT2271767T (en) |
PL (1) | PL2271767T3 (en) |
PT (1) | PT2271767T (en) |
SI (1) | SI2271767T1 (en) |
WO (1) | WO2009124293A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009137255A2 (en) | 2008-04-16 | 2009-11-12 | Hudsonalpha Institute For Biotechnology | Method for evaluating and comparing immunorepertoires |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
US8501449B2 (en) | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
US20120185176A1 (en) | 2009-09-30 | 2012-07-19 | Natera, Inc. | Methods for Non-Invasive Prenatal Ploidy Calling |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
CA3037126C (en) | 2010-05-18 | 2023-09-12 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
JP6328934B2 (en) | 2010-12-22 | 2018-05-23 | ナテラ, インコーポレイテッド | Noninvasive prenatal testing |
CN103797366A (en) | 2011-01-14 | 2014-05-14 | Cb生物技术公司 | Immunodiversity assessment method and its use |
JP6153874B2 (en) | 2011-02-09 | 2017-06-28 | ナテラ, インコーポレイテッド | Method for non-invasive prenatal ploidy calls |
US11782053B2 (en) | 2011-09-28 | 2023-10-10 | iRepertoire, Inc. | Identification of antigen-specific adaptive immune responses using ARM-PCR and high-throughput sequencing |
US9121051B2 (en) | 2011-10-31 | 2015-09-01 | Arkray, Inc. | Method of determining the abundance of a target nucleotide sequence of a gene of interest |
EP2774995A4 (en) | 2011-10-31 | 2015-04-29 | Arkray Inc | Method for measuring abundance of genes |
WO2013071258A1 (en) | 2011-11-11 | 2013-05-16 | Icubate, Inc. | Systems and methods for performing amplicon rescue multiplex polymerase chain reaction (pcr) |
US20160034637A1 (en) * | 2013-02-11 | 2016-02-04 | Cb Biotechnologies, Inc. | Method for evaluating an immunorepertoire |
US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
EP3134541B1 (en) | 2014-04-21 | 2020-08-19 | Natera, Inc. | Detecting copy number variations (cnv) of chromosomal segments in cancer |
CN104388579B (en) * | 2014-12-16 | 2018-11-09 | 上海速芯生物科技有限公司 | A kind of Arm-PCR detection methods of genetically engineered soybean and its derived varieties |
CN104611457B (en) * | 2015-03-04 | 2019-05-10 | 上海速芯生物科技有限公司 | Arm-PCR primer design method for multiple target point gene magnification |
CA2978751A1 (en) * | 2015-03-06 | 2016-09-15 | iRepertoire, Inc. | Method for measuring a change in an individual's immunorepertoire |
WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
DE102015012691A1 (en) | 2015-09-28 | 2017-03-30 | Biotecon Diagnostics Gmbh | Method for the quantitative detection of Vibrio parahaemolyticus, Vibrio vulnificus and Vibrio cholerae |
US11047011B2 (en) * | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
GB201704754D0 (en) * | 2017-01-05 | 2017-05-10 | Illumina Inc | Kinetic exclusion amplification of nucleic acid libraries |
RU2019131022A (en) * | 2017-03-09 | 2021-04-10 | айРепертуар, Инк. | MULTIPLEX POLYMERASE CHAIN REACTION WITH AVOIDING DIMER FORMATION FOR AMPLIFICATION OF MULTIPLE TARGET SEQUENCES |
WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
WO2019196087A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of cancer treatment using tumor antigen-specific t cells |
WO2019196088A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
CN109055500A (en) * | 2018-09-13 | 2018-12-21 | 中国人民解放军疾病预防控制所 | A kind of fluorescence ring mediated isothermal amplification method based on molecular beacon |
GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
EP3908678A1 (en) | 2019-01-10 | 2021-11-17 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
GB202005779D0 (en) | 2020-04-21 | 2020-06-03 | Scancell Ltd | Anti-tumour immune responses |
GB202018395D0 (en) | 2020-11-23 | 2021-01-06 | Scancell Ltd | Immunotherapy |
JP7457338B2 (en) * | 2021-03-11 | 2024-03-28 | セニジェン カンパニー リミテッド | Primer set for detecting food poisoning bacteria using next-generation sequencing method and method for detecting food poisoning bacteria using said primer set |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874557A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
US20070128617A1 (en) * | 2003-05-15 | 2007-06-07 | Ghazala Hashmi | Hybridization-mediated analysis of polymorphisms |
US20070190540A1 (en) * | 2005-09-01 | 2007-08-16 | Corbett Life Science Pty Ltd | Methods for the amplification, quantitation and identification of nucleic acids |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629158A (en) * | 1989-03-22 | 1997-05-13 | Cemu Bitecknik Ab | Solid phase diagnosis of medical conditions |
EP0409159B1 (en) * | 1989-07-18 | 1998-11-25 | Shimadzu Corporation | Method for testing causative microorganism of food poisoning and reagents therefor |
US5693502A (en) * | 1990-06-11 | 1997-12-02 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
US5763173A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
DE69433201T2 (en) * | 1994-02-28 | 2004-07-29 | Shimadzu Corp. | Oligonucleotides and methods for the detection of bacteria |
US5882856A (en) * | 1995-06-07 | 1999-03-16 | Genzyme Corporation | Universal primer sequence for multiplex DNA amplification |
EP0912761A4 (en) * | 1996-05-29 | 2004-06-09 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
DE19849348A1 (en) * | 1998-10-26 | 2000-04-27 | Univ Ludwigs Albert | Identification and/or sequencing of an unknown DNA or RNA sequence adjacent to a known DNA or RNA region comprises linker-mediated PCR following amplification by linear PCR |
US6312913B1 (en) * | 2000-07-21 | 2001-11-06 | Incyte Genomics, Inc. | Method for isolating and characterizing nucleic acid sequences |
WO2004099439A1 (en) * | 2003-05-09 | 2004-11-18 | Tsinghua University | Methods and compositions for optimizing multiplex pcr primers |
NZ546903A (en) * | 2003-10-13 | 2009-06-26 | Genaco Biomedical Products Inc | Method and kit for primer based amplification of nucleic acids |
US20060141518A1 (en) * | 2004-03-24 | 2006-06-29 | Lao Kai Q | Detection of gene expression |
ES2741546T3 (en) * | 2004-03-31 | 2020-02-11 | Massachusetts Gen Hospital | Method to determine the response of cancer to treatments directed at the epidermal growth factor receptor |
FR2860802B1 (en) * | 2004-07-28 | 2008-02-22 | Bertin Technologies Sa | METHOD FOR ENABLING CHIMILUMINESCENCE READING OF A CHIP |
KR100671501B1 (en) * | 2005-02-28 | 2007-01-19 | 삼성에버랜드 주식회사 | Primer for detecting food poisoning and method for rapid detection of food born pathogene |
US20060269934A1 (en) * | 2005-03-16 | 2006-11-30 | Applera Corporation | Compositions and methods for clonal amplification and analysis of polynucleotides |
ES2404311T3 (en) * | 2005-04-12 | 2013-05-27 | 454 Life Sciences Corporation | Methods for determining sequence variants using ultra-deep sequencing |
JP2007274934A (en) * | 2006-04-04 | 2007-10-25 | Nippon Meat Packers Inc | Primer set and method for detecting food poisoning bacterium |
-
2009
- 2009-04-03 WO PCT/US2009/039552 patent/WO2009124293A1/en active Application Filing
- 2009-04-03 CN CN2009801189681A patent/CN102066573A/en active Pending
- 2009-04-03 PT PT97278170T patent/PT2271767T/en unknown
- 2009-04-03 CN CN201510250072.6A patent/CN104928335A/en active Pending
- 2009-04-03 PL PL09727817T patent/PL2271767T3/en unknown
- 2009-04-03 US US12/418,532 patent/US7999092B2/en active Active
- 2009-04-03 DK DK09727817.0T patent/DK2271767T3/en active
- 2009-04-03 JP JP2011503231A patent/JP5811483B2/en active Active
- 2009-04-03 HU HUE09727817A patent/HUE029914T2/en unknown
- 2009-04-03 ES ES09727817.0T patent/ES2586457T3/en active Active
- 2009-04-03 LT LTEP09727817.0T patent/LT2271767T/en unknown
- 2009-04-03 AU AU2009231582A patent/AU2009231582B2/en active Active
- 2009-04-03 SI SI200931497A patent/SI2271767T1/en unknown
- 2009-04-03 EP EP09727817.0A patent/EP2271767B1/en active Active
- 2009-04-03 CN CN201710627329.4A patent/CN107385040B/en active Active
- 2009-04-03 BR BRPI0911082-8A patent/BRPI0911082A2/en not_active Application Discontinuation
-
2011
- 2011-08-15 US US13/210,331 patent/US20120171725A1/en not_active Abandoned
-
2015
- 2015-09-04 JP JP2015174617A patent/JP2016013133A/en active Pending
-
2016
- 2016-07-21 HR HRP20160923TT patent/HRP20160923T1/en unknown
- 2016-08-09 CY CY20161100781T patent/CY1117891T1/en unknown
-
2018
- 2018-04-19 HK HK18105098.0A patent/HK1245846A1/en unknown
-
2022
- 2022-04-28 US US17/732,384 patent/US20220251618A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874557A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
US20070128617A1 (en) * | 2003-05-15 | 2007-06-07 | Ghazala Hashmi | Hybridization-mediated analysis of polymorphisms |
US20070190540A1 (en) * | 2005-09-01 | 2007-08-16 | Corbett Life Science Pty Ltd | Methods for the amplification, quantitation and identification of nucleic acids |
Non-Patent Citations (2)
Title |
---|
HEATH ET AL., J. MED. GENET., vol. 37, 2000, pages 272 - 280 |
See also references of EP2271767A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009137255A2 (en) | 2008-04-16 | 2009-11-12 | Hudsonalpha Institute For Biotechnology | Method for evaluating and comparing immunorepertoires |
Also Published As
Publication number | Publication date |
---|---|
DK2271767T3 (en) | 2016-08-29 |
EP2271767B1 (en) | 2016-06-29 |
BRPI0911082A2 (en) | 2015-08-04 |
CY1117891T1 (en) | 2017-05-17 |
JP2011516069A (en) | 2011-05-26 |
LT2271767T (en) | 2016-09-26 |
EP2271767A1 (en) | 2011-01-12 |
US20220251618A1 (en) | 2022-08-11 |
CN107385040A (en) | 2017-11-24 |
PL2271767T3 (en) | 2017-01-31 |
AU2009231582B2 (en) | 2015-02-26 |
JP5811483B2 (en) | 2015-11-11 |
US20090253183A1 (en) | 2009-10-08 |
JP2016013133A (en) | 2016-01-28 |
CN104928335A (en) | 2015-09-23 |
HRP20160923T1 (en) | 2016-10-21 |
SI2271767T1 (en) | 2016-12-30 |
US20120171725A1 (en) | 2012-07-05 |
EP2271767A4 (en) | 2011-08-24 |
CN102066573A (en) | 2011-05-18 |
HUE029914T2 (en) | 2017-04-28 |
ES2586457T3 (en) | 2016-10-14 |
PT2271767T (en) | 2016-08-18 |
HK1245846A1 (en) | 2018-08-31 |
CN107385040B (en) | 2022-02-15 |
AU2009231582A1 (en) | 2009-10-08 |
US7999092B2 (en) | 2011-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220251618A1 (en) | Amplicon rescue multiplex polymerase chain reaction for amplification of multiple targets | |
JP7110155B2 (en) | Multiplex pyrosequencing using non-interfering, noise-canceling polynucleotide identification tags | |
US9222126B2 (en) | Methods for point-of-care detection of nucleic acid in a sample | |
US8673595B2 (en) | Sample analysis method and assay kit used therein | |
EP2130929B1 (en) | Internally controlled multiplex detection and quantification of microbial nucleic acids | |
WO2009087685A2 (en) | Method for detection of hepatitis nucleic acid and uses thereof | |
EP2598653B1 (en) | Generic pcr | |
EP2627787A2 (en) | Quantitative multiplexed identification of nucleic acid targets | |
US9175332B2 (en) | Generic PCR | |
JP2015019591A (en) | Nucleic acid chromatography | |
JP2003144153A (en) | Method for detecting gene, primer for detecting gene, dna microarray and kit for detecting gene | |
US20230235415A1 (en) | Method of detection | |
WO2016209938A1 (en) | Compositions and methods for processing a biological sample | |
WO2024134572A1 (en) | Sequences and methods for crispr-based detection of omicron 5 variant of sars-cov-2 | |
Schewe et al. | PCR-ELISA 24 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980118968.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09727817 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011503231 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009231582 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2344/MUMNP/2010 Country of ref document: IN Ref document number: 2009727817 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009231582 Country of ref document: AU Date of ref document: 20090403 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0911082 Country of ref document: BR Kind code of ref document: A2 Effective date: 20101004 |